Sign Up to like & get
recommendations!
1
Published in 2022 at "Brain and Behavior"
DOI: 10.1002/brb3.2672
Abstract: Levodopa and carbidopa are reported to be degraded by magnesium oxide (MgO), which is often used as a laxative for patients with Parkinson's disease (PD). Ascorbic acid (AsA) can stabilize levodopa and carbidopa solutions; however,…
read more here.
Keywords:
levodopa carbidopa;
degradation levodopa;
ascorbic acid;
magnesium oxide ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Chinese Journal of Analytical Chemistry"
DOI: 10.1016/s1872-2040(17)61021-1
Abstract: Abstract Levodopa, the metabolic precursor of dopamine, is usually administrated in combination with carbidopa to control dopamine levels in an appropriate manner and reduce side effects in the treatment of Parkinson's disease. In this study,…
read more here.
Keywords:
levodopa carbidopa;
gold nanoparticles;
line;
nanoparticles catalyzed ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Biochemical Journal"
DOI: 10.1042/bcj20210851
Abstract: IDO1 is an immunomodulatory enzyme responsible for tryptophan catabolism. Its expression in immune cells, especially the DCs, has attracted attention because it leads to tryptophan depletion at the immunological synapse, thereby causing T-cell anergy and…
read more here.
Keywords:
tumor growth;
expression;
ido1 expression;
cancer ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "International Journal of Neuroscience"
DOI: 10.1080/00207454.2016.1193862
Abstract: Carbidopa/levodopa enteral suspension (CLES; Duopa) is a suspension or gel formulation of carbidopa/levodopa that is approved by the USA Food and Drug Administration for the treatment of advanced Parkinson's disease patients with motor fluctuations. CLES…
read more here.
Keywords:
pump;
carbidopa levodopa;
levodopa enteral;
enteral suspension ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2785
Abstract: Background/Hypothesis: The amino acid transporter SLC6A14 is upregulated in estrogen receptor (ER)-positive breast cancer, a subtype that represents 75-80% of all breast cancers. Obesity/overweight increases the risk of breast cancer due to estrogen generated from…
read more here.
Keywords:
methyltryptophan;
breast;
breast cancer;
positive breast ... See more keywords